Farnesoid X receptor agonists for primary biliary cirrhosis

Current Opinion in Gastroenterology

Volumn 27, Issue 3, 2011, Pages 285-288

  Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

farnesoid X receptor; nuclear receptors; primary biliary cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; BILE ACID; CHENODEOXYCHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARNESOID X RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LIVER X RECEPTOR; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR;

ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; HOMEOSTASIS; HUMAN; LIVER REGENERATION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS;

BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; GASTROINTESTINAL AGENTS; HUMANS; LIVER CIRRHOSIS, BILIARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79955055532     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32834452c8     Document Type: Article

References (32)

1. Elfaki DA, Bjornsson E, Lindor KD. Review article: nuclear receptors and liver disease - current understanding and new therapeutic implications. Aliment Pharmacol Ther 2009; 30:816-825.
2. Tobin JF, Freedman LP. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Trends Endocrinol Metab 2006; 17:284-290. (Pubitemid 44287472)
3. McEwan IJ. Nuclear receptors: one big family. Methods Mol Biol 2009; 505:3-18.
4. Karpen SJ. Nuclear receptor regulation of hepatic function. J Hepatol 2002; 36:832-850. (Pubitemid 35177416)
5. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94:1169-1186. (Pubitemid 40904182)
6. Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr Opin Investig Drugs 2008; 9:247-255. (Pubitemid 351323377)
7. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89:147-191.
8. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008; 65:2461-2483.
9. Trauner M, Wagner M, Fickert P, et al. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 2005; 39 (4 Suppl 2):S111-S124. (Pubitemid 40397024)
10. Huang W, Zhang J, Moore DD. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J Clin Invest 2004; 113:137-143. (Pubitemid 38541640)
11. Zollner G, Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 2009; 156:7-27.
12. Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125:825-838. (Pubitemid 37070700)
13. Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005; 42:420-430. (Pubitemid 41061095)
14. Zollner G, Trauner M. Mechanisms of cholestasis. Clin Liver Dis 2008; 12:1- 26; vii. (Pubitemid 351163143)
15. Jung D, Mangelsdorf DJ, Meyer UA. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 2006; 281:19081-19091. (Pubitemid 44035412)
16. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102:731-744.
17. AnanthanarayananM, Balasubramanian N, MakishimaM, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 2001; 276:28857-28865.
18. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistanceassociated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277:2908-2915. (Pubitemid 34953324)
19. Pellicciari R, Fiorucci S, Camaioni E, et al. 6Alpha-ethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45:3569-3572. (Pubitemid 34856095)
20. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. J Hepatol 2003; 38:434-440. (Pubitemid 36399245)
21. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49:297-305.
22. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217-225.
23. Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312:233-236.
24. Kim I, Morimura K, Shah Y, et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007; 28:940-946. (Pubitemid 47072176)
25. Yang F, Huang X, Yi T, et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007; 67:863-867.
26. Pineda Torra I, Claudel T, Duval C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17:259-272. (Pubitemid 36183149)
27. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116:1102-1109.
28. Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005; 314:584-595. (Pubitemid 41043838)
29. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127:1497-1512. (Pubitemid 39457775)
30. Fiorucci S, Rizzo G, Antonelli E, et al. Cross-talk between farnesoid-Xreceptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005; 315:58-68. (Pubitemid 41380498)
31. MasonA LV, Lindor K, Hirschfield G, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010; 52(Suppl 1): S1-S2.
32. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123:1238-1251.